LG Chem, a leader in diabetes medicine, elevated awareness of Korean diabetes treatment during a symposium held at the Philippine College of Endocrinology, Diabetes & Metabolism conference. Collaborating with Korean endocrinologists, LG Chem shared insights into diabetes treatment and management, with a spotlight on their innovative drug, Zemiglo.

Korean professors, serving as keynote speakers, outlined tailored treatment options for young diabetic patients and highlighted Zemiglo's clinical advantages to over 250 Filipino endocrinologists. They addressed the rising prevalence of adult diabetic patients under 40 in the Philippines and advocated for proactive initial combination therapy with Zemiglo and metformin over sequential monotherapy. Moreover, they underscored the efficacy of Zemimet, a combination drug, based on extensive clinical trials showcasing stable blood glucose levels and minimal dose adjustments, even for patients with kidney impairment.

Reflecting on the academic exchange, the Korean professors emphasized the event's role in elevating Korea's reputation as a medical hub in diabetes care. LG Chem aims to extend this initiative, titled the "Enhancement Project for the Medical Status of Korea and the Positioning of South Korean New Drugs," to Thailand and later to Central and South American regions.

In-Cheol Hwang, Executive Vice President and Head of Primary Care Business at LG Chem, affirmed the company's commitment to meeting the needs of Filipino physicians and improving local diabetic patient management through continued academic events.

Meanwhile, LG Chem has been actively expanding Zemiglo's presence since 2017, targeting strategic markets in Southeast Asia and Central and South America. With exports reaching approximately $11 million last year, the company anticipates surpassing $15 million in revenue this year. Plans are underway to introduce Zemiglo to new markets such as Brazil, Malaysia, Colombia, Ecuador, and to launch a new combination drug, Zemidapa.